

CONTACT - Media:

Amsterdam +31.20.721.4488
Lisbon +351.217.900.029

Brussels +32.2.509.1392
Paris +33.1.70.48.24.45

CONTACT - Investor Relations:

+33.1.70.48.24.17

ENTERNEXT WELCOMES MITHRA PHARMACEUTICALS TO EURONEXT BRUSSELS



Brussels, 30 June 2015 – EnterNext, the Euronext subsidiary designed to promote and grow the market for mid and small capitalisations, welcomes today Mithra Pharmaceuticals SA, a Belgian company focused on women’s health, on the regulated market of Euronext Brussels.

Mithra is a pharmaceutical company focused on the development, manufacturing and commercialisation of proprietary, innovative and differentiated drugs and complex generic products dedicated to female healthcare. Mithra is specialised in four different domains of Women’s Health: contraception and fertility, menopause and osteoporosis, gynecological infections and cancers.

Mithra (ticker code: MITRA) issued 6.023.809 new shares at a reference price of EUR 12 per share, giving the company an initial market capitalisation of EUR 366.5 million. The transaction raised a total of EUR 72.3 million.

François Fornieri, CEO of Mithra Pharmaceuticals, said : *“It is a great honour for Mithra to inaugurate the new Euronext offices with this first IPO. For us, this is the result of four months of intensive work to reach a market capitalization of more than 366 million euros for Mithra. We have managed to raise 72,3 million euros through this IPO, an amount which will enable us to both finance research projects and to grow as a company.”*

Vincent Van Dessel, CEO of Euronext Brussels, declared: *“We are delighted to host such a successful company on our European market. The listing of Mithra on Europe’s leading stock exchange demonstrates the attractiveness of public equity as a source of financing the real economy and helping companies achieve their funding needs.”*

Alain Baetens, Head of Listings of Euronext Brussels, added: *“The IPO of Mithra was warmly welcomed by institutional and retail investors, which stresses the quality of Euronext Brussels as a major financing centre for innovative and ambitious entrepreneurs. It is the largest pharmaceutical IPO in the euro zone this year. With the support of the Enternext solutions for mid & small caps, Mithra will benefit from the access to a wide range of services that will help to raise its visibility and liquidity as a listed company.”*

To celebrate the listing, François Fornieri, CEO of Mithra Pharmaceuticals, rang the bell in Brussels to open trading on Euronext's European markets.



ING Belgium and KBC Securities acted as joint global coordinators and joint bookrunners.

CONTACTS - Euronext

Caroline Nico (Europe): +33 1 49 27 10 74; cnico@euronext.com
 Alice Jentink (Amsterdam): +31 20 550 4488; ajentink@euronext.com
 Jean-Yves Daxhelet (Brussels): +32 2 213 13 03; jean-yves.daxhelet@interelgroup.com
 Sandra Machado (Lisbon): +351 217 900 029; smachado@euronext.com
 Laura Panhard (Paris): +33 1 49 27 10 82; lpahard@euronext.com

CONTACTS – Mithra Pharmaceuticals

Julie Dessart, Head of Communications
 +32 4 349 28 22
 +32 475 864 175
jdessart@mithra.com

Jean-Manuel Fontaine
 Public Relations
 +32 4 349 28 32
 +32 476 965 459
jmfontaine@mithra.com

François Fornieri, CEO / Steven Peters, CFO
 +32 4 349 28 22

About Mithra Pharmaceuticals

Mithra Pharmaceuticals SA, founded in 1999 as a spin-off of the University of Liège by Mr. François Fornieri and Prof. dr. Jean-Michel Foidart, is a pharmaceutical company focused on women's health. Mithra's mission is to support and assist women at every stage of their life, thereby improving their overall quality of life. As such the Company aims to become a worldwide leader in women's health by developing, manufacturing and commercialising proprietary, innovative and differentiated drugs and generic

products in four therapeutic fields of women's health, fertility and contraception, menopause and osteoporosis, vaginal infections and cancers.

Mithra has a total headcount of approximately 85 staff members and is headquartered in Liège, Belgium. Further information can be found at: www.mithra.com

About EnterNext

Launched in May 2013, EnterNext is the subsidiary of the Euronext Group designed to develop and promote its stock markets specifically for small and medium-size enterprises (SMEs). Drawing on its pan-European presence, EnterNext brings together all Euronext Group initiatives for companies with market capitalisations under €1 billion, including companies listed in the B and C compartments of its regulated European markets and on Alternext, the market tailored to the needs of SMEs. EnterNext plays an active role in facilitating SMEs' access to financial markets, helping them generate the funds they need to grow at regional, national and pan-European level.

About Euronext

Euronext is the primary exchange in the Euro zone with more than 1 300 listed issuers worth €3.2 trillion in market capitalization, an unmatched blue chip franchise consisting of 24 issuers in the EURO STOXX 50® benchmark and a strong diverse domestic and international client base.

Euronext operates regulated and transparent equity and derivatives markets. Its total product offering includes Equities, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. Euronext operates regulated markets, Alternext and the Free Market; in addition it offers EnterNext, which facilitates SMEs' access to capital markets.

Disclaimer

This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided "as is" without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext's subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.

This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at www.euronext.com/terms-use.

© 2015, Euronext N.V. - All rights reserved.